A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
C4 Therapeutics, Inc.
CCCC
$281M
Mkt Cap
$3.40
-6.85%
C4 Therapeutics, Inc. (CCCC) has a 5-year average return on invested capital (ROIC) of -39.9%. This is below average and may indicate limited pricing power.
C4 Therapeutics, Inc. (CCCC) has a market capitalization of $281M. It is classified as a small-cap stock.
C4 Therapeutics, Inc. (CCCC) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.07%.
C4 Therapeutics, Inc. (CCCC) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
C4 Therapeutics, Inc. (CCCC) generated $-99 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
C4 Therapeutics, Inc. (CCCC) has a debt-to-equity ratio of 0.40. This indicates a conservatively financed balance sheet.
C4 Therapeutics, Inc. (CCCC) reported earnings per share (EPS) of $-1.27 in its most recent fiscal year.
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives. Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Our strategy is to develop degraders that modulate clinically validated disease pathways with best-in-class or first-in-class potential to address significant unmet patient needs. To date, our degraders have demonstrated oral bioavailability and catalytic activity, and we have also leveraged our capability to design compounds that are brain penetrant.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | 46M |
| Net Income | -105M | -105M | -105M | -132M | -128M | -84M |
| EPS | $-1.27 | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
| Free Cash Flow | -99M | -99M | -65M | -109M | -111M | -88M |
| ROIC | -50.0% | -44.4% | -45.6% | -48.7% | -36.7% | -24.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.40 | 0.30 | 0.00 | 0.04 | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -115M | -115M | -120M | -139M | -130M | -82M |
| Operating Margin | 0.0% | - | - | - | - | -179.4% |
| ROE | -40.9% | -44.4% | -45.6% | -49.5% | -37.8% | -25.0% |
| Shares Outstanding | 83M | 83M | 69M | 50M | 49M | 46M |
| Metric | 2019 | |||||||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 21M | 33M | 46M | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 48M | 78M | 95M | 118M | 118M | 111M | 104M | 104M |
| SG&A | 8.8M | 15M | 33M | 43M | 42M | 42M | 36M | 36M |
| EBIT | -35M | -60M | -82M | -130M | -139M | -120M | -115M | -115M |
| Op. Margin | -165.8% | -182.1% | -179.4% | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -43M | -66M | -84M | -128M | -132M | -105M | -105M | -105M |
| Net Margin | -199.1% | -199.8% | -183.2% | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 2.4M | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -30.0% | -22.8% | -24.3% | -36.7% | -48.7% | -45.6% | -44.4% | -50.0% |
| ROE | N/A | -23.6% | -25.0% | -37.8% | -49.5% | -45.6% | -44.4% | -40.9% |
| ROA | -36.0% | -16.6% | -18.5% | -27.3% | -32.8% | -29.0% | -29.6% | -29.2% |
| Cash Flow | ||||||||
| Op. Cash Flow | 56M | -67M | -87M | -106M | -107M | -65M | -99M | -99M |
| Free Cash Flow | 54M | -68M | -88M | -111M | -109M | -65M | -99M | -99M |
| Owner Earnings | 52M | -72M | -110M | -138M | -136M | -97M | -120M | -120M |
| CapEx | 1.3M | 650K | 1.3M | 5.5M | 1.7M | 180K | 607K | 607K |
| Maint. CapEx | 1.6M | 1.6M | 1.5M | 1.7M | 1.9M | 1.8M | 2.0M | 2.0M |
| Growth CapEx | 0 | 0 | 0 | 3.8M | 0 | 0 | 0 | 0 |
| D&A | 1.6M | 1.6M | 1.5M | 1.7M | 1.9M | 1.8M | 2.0M | 2.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 30K | 194K | 0 | 0 | 110K | 194K | 193K | 193K |
| Buyback Yield | N/A | 0.0% | N/A | N/A | 0.0% | 0.1% | 0.1% | 0.1% |
| Stock-Based Comp | 1.6M | 3.4M | 22M | 30M | 27M | 30M | 19M | 19M |
| Debt Repayment | 0 | 0 | 500K | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | -362M | -266M | -355M | -408M | -257M | N/A | -75M |
| Cash & Equiv. | 91M | 182M | 76M | 30M | 127M | 55M | 75M | 75M |
| Long-Term Debt | N/A | 10M | 11M | 9.2M | 0 | N/A | N/A | N/A |
| Debt/Equity | -2.06 | 0.04 | 0.11 | 0.04 | 0.00 | 0.30 | 0.40 | 0.00 |
| Interest Coverage | N/A | -49.2 | -62.8 | -86.4 | -139.0 | N/A | N/A | N/A |
| Equity | -112M | 281M | 390M | 289M | 246M | 216M | 257M | 257M |
| Total Assets | 118M | 400M | 507M | 431M | 376M | 350M | 359M | 359M |
| Total Liabilities | 230M | 119M | 117M | 142M | 130M | 134M | 102M | 102M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -117M | -184M | -268M | -396M | -528M | -634M | -739M | -739M |
| Working Capital | 63M | 337M | 274M | 243M | 228M | 213M | 225M | 225M |
| Current Assets | 97M | 381M | 326M | 288M | 271M | 258M | 258M | 258M |
| Current Liabilities | 34M | 44M | 51M | 45M | 43M | 45M | 33M | 33M |
| Per Share Data | ||||||||
| EPS | -31.03 | -5.83 | -1.82 | -2.62 | -2.67 | -1.52 | -1.27 | -1.27 |
| Owner EPS | 1.21 | -1.48 | -2.39 | -2.81 | -2.74 | -1.39 | -1.45 | -1.45 |
| Book Value | -2.60 | 5.76 | 8.45 | 5.91 | 4.96 | 3.12 | 3.10 | 3.10 |
| Cash Flow/Share | 1.29 | -1.38 | -1.89 | -2.17 | -2.15 | -0.94 | -1.19 | -1.25 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 43.1M | 48.7M | 46.1M | 48.9M | 49.6M | 69.3M | 82.7M | 82.7M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 6.2 | 3.9 | 0.9 | 1.2 | 1.2 | 0.7 | 1.1 |
| Price/Sales | N/A | 42.2 | 39.8 | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -3.9% | -5.8% | -40.7% | -36.3% | -24.9% | -56.7% | -35.3% |
| Market Cap | N/A | 1.7B | 1.5B | 274M | 299M | 263M | 175M | 281M |
| Avg. Price | N/A | 28.72 | 39.51 | 13.27 | 3.62 | 6.18 | 2.31 | 3.40 |
| Year-End Price | N/A | 35.88 | 32.86 | 5.60 | 6.03 | 3.79 | 2.12 | 3.40 |
C4 Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
C4 Therapeutics, Inc. (CCCC) has a return on equity (ROE) of -44.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for C4 Therapeutics, Inc. (CCCC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
C4 Therapeutics, Inc. (CCCC) has a book value per share of $3.10, based on its most recent annual SEC filing.